BLFS — BioLife Solutions, Inc.

BioLife Solutions Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $28.1 million, up 31% year-over-year.
• Cell Processing Revenue: $25.4 million, a 33% increase year-over-year.
• Adjusted EBITDA: $7.8 million (28% of revenue), compared to $5 million (23% of revenue) in Q3 2024.
• GAAP Net Income: $621,000 ($0.01 per share) versus a net loss of $471,000 in Q3 2024.
• Gross Margin: GAAP gross margin at 62% (down from 63% in Q3 2024); adjusted gross margin at 64% (down from 67%).
• Operating Expenses: GAAP operating expenses increased to $28.2 million from $21.8 million in Q3 2024.
• Cash and Marketable Securities: Approximately $98.4 million as of September 30, 2025, excluding proceeds from the recent sale of the evo Cold Chain product line.

2. Strategic Updates and Business Highlights

• BioLife sold its evo Cold Chain logistics product line for approximately $25 million, allowing a sharper focus on its core competencies in cell processing.
• The company is transitioning to a more direct sales model, with a shift in the direct versus distributor sales mix to 70-30.
• BioLife's biopreservation media (BPM) products are embedded in 16 approved therapies and over 250 commercially sponsored CGT clinical trials, maintaining a strong market presence.
• The company is focused on cross-selling additional products to existing BPM customers, which could significantly increase revenue per patient dose.

3. Forward Guidance and Outlook

• Revised Revenue Guidance: Total revenue expected to be $95 million to $96 million for 2025, reflecting a growth rate of 27% to 29% year-over-year.
• Cell Processing Revenue Guidance: Increased to $93 million to $94 million, representing a growth rate of 26% to 28%.
• The company anticipates a sequential revenue decrease in Q4 due to the pull-forward of a $1.3 million order from Q3.
• Expectations for continued growth driven by existing commercial customers and late-stage clinical programs, with a focus on maintaining strong margins.

4. Bad News, Challenges, or Points of Concern

• Adjusted gross margins decreased due to a one-time inventory reserve and a less favorable product mix.
• Operating expenses rose significantly, attributed to increased costs associated with higher revenues and stock-based compensation.
• There is uncertainty regarding the impact of broader market dynamics and potential funding challenges in the biotech sector, which could affect customer spending.

5. Notable Q&A Insights

• Pricing is expected to increase by 4% to 6% in 2026, with year-to-date pricing growth higher than list price increases.
• The company has added a small number of direct sales personnel focused on cross-selling, with cautious expansion plans based on return on investment.
• Discussions with customers indicate a stable funding environment, but the company remains in a wait-and-see mode regarding any potential impacts from external factors like government shutdowns.
• The CryoCase project is progressing, with expectations of a commitment from a large customer soon.

Overall, BioLife Solutions demonstrated strong financial performance in Q3 2025, with strategic initiatives aimed at enhancing profitability and market position. However, the company faces challenges related to margin pressures and external market conditions that could impact future growth.